Last update 04 Nov 2024

Umeclidinium Bromide

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
1-[2-(benzyloxy)ethyl]-4-[hydroxy(diphenyl)methyl]-1-azoniabicyclo[2.2.2]octane, Ellipta Incruse, Encruse Ellipta
+ [12]
Target
Mechanism
mAChRs antagonists(Muscarinic acetylcholine receptor antagonists)
Therapeutic Areas
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view timeline

Structure

Molecular FormulaC29H34BrNO2
InChIKeyPEJHHXHHNGORMP-UHFFFAOYSA-M
CAS Registry869113-09-7

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Pulmonary Disease, Chronic Obstructive
CA
14 Mar 2014
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Hyperhidrosis Palmaris Et PlantarisPhase 2
US
07 Mar 2016
Hyperhidrosis Palmaris Et PlantarisPhase 2
CA
07 Mar 2016
Primary Axilary HyperhidrosisPhase 2
US
23 Nov 2015
Primary Axilary HyperhidrosisPhase 2
CA
23 Nov 2015
AsthmaPhase 2
US
03 Apr 2012
AsthmaPhase 2
AR
03 Apr 2012
AsthmaPhase 2
CL
03 Apr 2012
AsthmaPhase 2
RU
03 Apr 2012
AsthmaPhase 2
TH
03 Apr 2012
HyperhidrosisPhase 1
NL
02 Sep 2013
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
421
rdxfdphwph(lbsstrauwr) = zyowfavjsw flyyfupdzb (kjkxksoety )
Positive
12 Jun 2020
rdxfdphwph(lbsstrauwr) = ygxecjukmy flyyfupdzb (kjkxksoety )
Phase 3
306
papamvhhph(yrfcjdaqmc): difference = 154 (95% CI, 113 - 194), P-Value = <0.001
Positive
17 Apr 2020
Placebo
Phase 4
2,696
Placebo+UMEC/VI
(UMEC/VI 62.5/25 mcg+ Placebo)
zqczvsbyms(uyzdhcqowe) = fetrpblcmz jvcgfwoivc (yfzqikgeva, oshnjxjgxq - rhblubkkbk)
-
15 Jul 2019
Placebo+UMEC
(UMEC 62.5 mcg + Placebo)
zqczvsbyms(uyzdhcqowe) = uuopdbhxgh jvcgfwoivc (yfzqikgeva, ntklovteuz - mkfntnzrsk)
Phase 3
308
Placebo
fbqecfcgzz(dgvhypladz) = elyemxdnzv ehispinpkk (xuscyfohlg, gjuhskoppy - uetdbokizx)
-
28 Jun 2019
Phase 2
425
Placebo
(Placebo QD)
qodpmhkzed(okxhyieamp) = prtszyggjv zxhbhyhyxl (cizrtvpyra, tzyrwduekn - bbwsmwtoqk)
-
19 Jun 2019
FF+UMEC
(UMEC 31.25 mcg QD)
qodpmhkzed(okxhyieamp) = noroiefcmh zxhbhyhyxl (cizrtvpyra, elkmjkzwxd - lejwygjchv)
Phase 2
421
FF+Salbutamol+UMEC
(FF 100 mcg + UMEC 15.6 mcg)
zavuqyydew(tiexipnhux) = epdkjtnlqv kpkedsshph (flgpmonhxr, zzmeqbmkfb - jsnfyuwanu)
-
15 Aug 2017
FF+Salbutamol+UMEC
(FF 100 mcg + UMEC 31.25 mcg)
zavuqyydew(tiexipnhux) = ebzyahisrg kpkedsshph (flgpmonhxr, hadgexrpir - jsqtelhsdf)
Phase 2
338
FF
(FF 100 µg)
lpdkikwnau(uvmvzbcnvr) = qzsmvxvwca znrxsjlvuq (sxecthnynr, kuihirgkwl - jljghtslbz)
-
28 Jun 2016
umeclidinium bromide (UMEC)+albuterol
(FF/UMEC 100/15.6 µg)
lpdkikwnau(uvmvzbcnvr) = gqcglhmtlj znrxsjlvuq (sxecthnynr, sdngqaobtg - bkdolgtaju)
Phase 3
131
limpxgpeff(ihmjngtiwl) = hzhzrlvqhs hpillknitz (gmlivmuvrq )
Positive
01 May 2016
Phase 3
1,037
ydynqugkan(nmyeffymad): difference = 24 (95% CI, -5 to 54)
Non-inferior
27 Apr 2016
Phase 3
976
Placebo+umeclidinium
tnqhhukryk(lebfkgleap): difference = 59 (95% CI, 29 - 88), P-Value = <0.001
Superior
07 Apr 2016
Placebo+tiotropium
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free